Percutaneous cryoablation of renal cell carcinoma smaller than 4 cm: Phase II clinical trial
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000011921
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
The mean tumor diameter: 2.1??+/- 0.6 (range 1.0-3.4) cm. The median follow up period: 60.1 (range 18.4-76.6) months. The cause specific and overall survival rates were 100% and 96.8% at 3 years, and 100% and 96.8% at 5 years, respectively. There was no local tumor progression or distant metastasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 33
Not provided
1) Patients with extra-renal tumor spread 2) Patients with vascular invasion like venous tumor thrombus 3) There is a vital organ or major vessel along expected puncture line. 4) Patients have allergy for alcohol or contrast medium (iodine). 5) Patients have severe comorbidities as follows: a) Congestive heart failure failure (>=NYHA III) b) Active or uncontrolled clinically serious infection (excluding chronic hepatitis) 6) Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, excluding carcinoma in situ, cancers corresponding to intraepithelial or intramucosal neoplasia, any cancer curatively treated or, breast cancer/prostatic cancer in carcinostatic state. 7) Patients have a fever more than 38 C degree. 8) Patients is difficult to receive imaging evaluation like computed tomography (CT) or magnetic resonance imaging (MRI) 9) Female patients who are pregnant. 10) Any patients who is considered unsuitable for being enrolled in this clinical trial by an attending physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method